Select Transactions
|
| Sale of stock and conditional sale to |
|
|
$215 million + CVRs
February 2019
|
|
| Debt recapitalization and acquisition of NextWave Pharmaceuticals from |
|
|
$125 million
September 2018
|
|
| Majority recap by |
|
|
$125 million
April 2019
|
|
| Acquisition of generics business of |
|
|
$1.05 billion
June 2017
|
Torreya is a leading strategic M&A advisor to global life sciences companies. MORE
Torreya is one of the most active financial advisors on pharmaceutical-product asset sales. MORE
Torreya’s Capital Markets team arranges debt financings, royalty monetizations, IPOs, and private equity recapitalizations. MORE
Torreya is a leading advisor on pre-commercial and commercial-stage licensing deals. MORE
Creating Value Through Intelligent Borrowing
Opportunities in the Life Sciences Debt Market
Torreya’s report provides an overview of the evolving landscape of the Life Sciences debt market. Key points include:
- Debt is an important part of the balance sheet and is lightly used by life science companies.
- The market for debt has grown dramatically and broadened significantly.
- As the value of debt becomes more recognized, the landscape of borrowers will continue to evolve.
Click Here for Report Executive Summary | Click Here for Full Report